1. Dr Anthony Fok Neurologist and Neuro-ophthalmologist
MS Trials
Dr Anthony Fok
Neurologist and Neuro-ophthalmologist

3. Research and Development

4. IL-37 Study
Studying the role of a Interleukin-37 in inflammatory diseases
Thought: IL-37 is an inhibitor of inflammation
Check IL-37 levels in patients with inflammatory diseases and compare to patients without diseases
Need: Consent and blood taken.
Future: this may lead to drug development

5. Vitamin D is thought to play a role in MS
PrevANZ
Patients with a first clinical attack – Clinically isolated Syndrome
Test different doses of Vitamin D3
See whether it can delay or prevent a second episode that would lead to diagnosis of MS
Double blind
Placebo controlled
Treatment for 12 months
Collect blood and urine
Vitamin D – thought o play a role in MS. Since geographical areas with lower levels of UV radiation – ie have lower vit D synthesis in the skin have higher incidences of MS.
Vitamin D3 (cholecalciferol) is produced by the human body in response to sunlight and is also available through dietary sources, such as fish. 
Safety Efficacy/safety
Efficacy/safety and compare to other drug

6. Phase IV trial for Tecfidera (dimethyl Fumarate)
ESTEEM trial
Phase IV trial for Tecfidera (dimethyl Fumarate)
Include: all patients starting Tecfidera
Followup every 6 months
Monitor adverse effects
You need to complete questionnaires at each clinic visit – can be done online
Phase IV study – done after intervention has been marketed – monitor the effectiveness of the approved intervention and collect info on adverse effects

7. Multicentre, randomised, double blinded placebo controlled study
AFFINITY STUDY
Multicentre, randomised, double blinded placebo controlled study
Relapsing Remitting MS
Add on therapy to other therapies
- Interferon (beta1a, beta 1b, beta1a)
Dimethyl fumerate
Nataluzimab
Dx: RRMS
EDSS 2-6
MS disease duration <20 years
Relapse within 24 months and new lesions on MRI
Beta 1a avonex, betaferon – beta 1 b

9. Ask your friendly neurologist or MS nurse